Tseng Wen-Hsin, Chiang Ting-Yi, Ho Chung-Han, Huang Steven K, Chiu Allen W, Li Chien-Feng, Shiue Yow-Ling
Institute of Biomedical Science, National Sun Yat-sen University, Kaohsiung, Taiwan.
Division of Urology, Department of Surgery, Chi Mei Medical Center, Tainan, Taiwan.
Front Nutr. 2024 Dec 11;11:1433632. doi: 10.3389/fnut.2024.1433632. eCollection 2024.
This study investigates the complex relationship between body mass index (BMI) and bladder cancer outcomes, utilizing Taiwan's national database. Bladder cancer remains a significant health concern, especially in Taiwan, prompting a comprehensive retrospective analysis to explore the impact of obesity on survival outcomes.
A meticulous exclusion process, based on Taiwan National Health Insurance System Database, refined the initial dataset of 15,086 bladder cancer patients to 10,352. Categorizing patients into BMI groups (underweight, normal weight, and obesity), the study examined baseline characteristics, comorbidities, and survival outcomes. The analysis involved Cox regression and subgroup assessments stratified by clinical stage.
Among our patients, 71.5% are male, 78.5% are over 60 years of age, and 18.8% are between 45 and 60 years old. Despite a higher prevalence of comorbidities, obesity patients exhibited a more favorable prognosis, supporting the obesity paradox. The overall and specific mortality ratio of obesity patients were 0.76 fold and 0.82-fold compared with normal-weight patients (overall: 95% confidence interval [CI], 0.71-0.82, < 0.0001; specific: 95% CI, 0.75-0.90, p < 0.0001). Conversely, underweight patients displayed an increased risk of both overall and cancer-specific mortality compared to normal-weight patients ( < 0.0001).
This study highlights the potential protective role of higher BMI in bladder cancer survival, revealing a more favorable prognosis among obesity patients, highlighting the need for cautious interpretation and suggesting avenues for future research. These insights could guide BMI-targeted intervention strategies, allowing clinicians to consider BMI as a factor in personalized treatment planning for bladder cancer patients.
本研究利用台湾的国家数据库,调查体重指数(BMI)与膀胱癌预后之间的复杂关系。膀胱癌仍然是一个重大的健康问题,尤其是在台湾,这促使我们进行全面的回顾性分析,以探讨肥胖对生存结果的影响。
基于台湾国民健康保险系统数据库进行了细致的排除过程,将15086例膀胱癌患者的初始数据集精炼至10352例。将患者分为BMI组(体重过轻、正常体重和肥胖),研究检查了基线特征、合并症和生存结果。分析采用Cox回归和按临床分期分层的亚组评估。
在我们的患者中,71.5%为男性,78.5%年龄超过60岁,18.8%年龄在45至60岁之间。尽管肥胖患者合并症的患病率较高,但他们的预后更有利,这支持了肥胖悖论。与正常体重患者相比,肥胖患者的总体死亡率和特定死亡率分别为0.76倍和0.82倍(总体:95%置信区间[CI],0.71-0.82,<0.0001;特定:95%CI,0.75-0.90,p<0.0001)。相反,与正常体重患者相比,体重过轻的患者总体死亡率和癌症特异性死亡率均增加(<0.0001)。
本研究强调了较高BMI在膀胱癌生存中的潜在保护作用,揭示了肥胖患者预后更有利,强调了谨慎解释的必要性,并提出了未来研究的方向。这些见解可指导以BMI为目标的干预策略,使临床医生在为膀胱癌患者制定个性化治疗方案时将BMI作为一个因素加以考虑。